The Chennai-based Take Solutions' Life Sciences division is gearing up to address the clinical research needs of the emerging markets like Middle East, Africa and South East Asia with its PharmaReady and Pharmacovigilance solutions.
PharmaReady and Pharmacovigilance solutions are web-based simple products and offer better results at a faster pace. The company has a large base of customers from North America, European Union, Australia and China for these products.
"In the wake of the growing number of global multi-centric clinical trails which are taking off in the emerging markets, Take Solutions intends to increase its reach with these two offerings. With electronic submission or electronic Common Technical Document (eCTD) being mandated by regulatory majors, both these products stand to gain recognition among pharma and clinical research organisations," informed Ram Yeleswarapu, president and CEO, Take Solutions.
PharmaReady is a fully integrated web-based product and services solution suite includes document management, training records management, structured product labelling and submission services. As a fully 21 CFR Part 11 compliant solution based on Microsoft Windows technology, it is specifically designed for life science organisations where ease of installation, ease of use and affordability are the primary business drivers.
On the other hand, Pharmacovigilance solution helps to minimise the adverse drug reactions. It is power packed with the complete pharmacovigilance system, electronic reporting, fully integrated product register, MedDRA browser and search tool, easy migration of drug safety data, flexible and free-text search tool.
"We have been working with large pharma companies for the installation of these solutions. The two products have been designed in such a way to interpret the stringent regulatory guidelines. It has helped us to bag good deals from the global drug development companies," said the Take Solutions chief.
The installations of PharmaReady include Banner Pharmacaps; Global Pharmaceutical, Netherlands; Dermal Laboratories; Dermatological R&D and Marketing, United Kingdom; Sangart and Global Biopharmaceutical, San Diego.
"The drug safety surveillance solutions are offered via completely web-based, hosted, secure platform and this makes it easy for customers to implement this solution in a short time frame. The product is also relevant to the Indian market needs. The pricing structure is appealing not only to small and medium biopharmaceutical companies, but also for generic companies where the adverse events volume is generally less," noted Yeleswarapu.
The company, which began operations in 2000, has been serving clients in the Life Sciences space in over 12 countries with more than 300 customers.